Home/ Markets / Mark To Market/  Cadila Healthcare’s vaccine bet keeps sentiment upbeat

The news flow around covid-19 vaccines has kept Cadila Healthcare Ltd’s shares under the investors’ radar. The company has completed phase 2 clinical trials for ZyCoV-D, the indigenously developed vaccine, and has also received approvals to conduct phase 3 trials.

Of course, for the Street, the launch timeline is crucial for assessing the gains that Cadila can derive from it, as many other vaccines are already lined up for launch. If other vaccines are launched earlier, it can mean higher competitive intensity for Cadila at the time of launch.

Also Read | The race to take fashion retail online

Also, as Jefferies India analysts said in their research report: “As AZ (AstraZeneca) vaccine becomes commercially available, potential trial subjects will become increasingly tough to find."

In recovery mode
View Full Image
In recovery mode

Meanwhile, the company has said that it will be initiating phase 3 clinical trials with around 30,000 volunteers. ZyCoV-D was found to be safe, well-tolerated and immunogenic in the phase 1 and 2 clinical trials.

The successful launch can add to the company’s forward prospects and earnings estimates in spite of the launch of other vaccine brands, added analysts.

Surya Patra, an analyst at Phillip Capital, said: “We estimate this vaccine, if successful, could upgrade our FY22 earnings by about 50% and could be a big earnings as well as a valuation catalyst."

The company continues to benefit from its existing covid treatment drug portfolio in India.

With a restructured India business (distribution and field force restructuring, etc.) it is eyeing higher India growth trajectory. The company’s India business grew 11% year-on-year during Q2.

The US business, which had faced pricing pressure earlier, is also stabilizing now, supported by new product launches. US sales grew 18% year-on-year during Q2.

Timely approvals of complex opportunities, though, will be key to offset the erosion in the base business, said analysts.

Overall, the company sees much improved India and US business outlook.

At 486 apiece, the stock is trading at close to 21 times one-year forward earnings estimates, which is in line with the three-year average of 20x that it traded at. For a significant re-rating from the current levels, the launch of the vaccine will be crucial.

Ujjval Jauhari
Ujjval Jauhari is a deputy editor at Mint, with over a decade of experience in newspapers and digital news platforms. He is skilled in storytelling, reporting, analysing and writing about stocks, investment ideas, markets, corporates and more. He is based in New Delhi.
Know your inner investor Do you have the nerves of steel or do you get insomniac over your investments? Let’s define your investment approach.
Take the test
Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Updated: 06 Jan 2021, 05:14 AM IST
Recommended For You

Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!

Let’s get started
Get alerts on WhatsApp
Set Preferences My Reads Watchlist Feedback Redeem a Gift Card Logout